Published by
@ShahidNShah
@ShahidNShah
0-50Biotechnology
, Boston, Massachusetts, 02118, United States
BioSymetrics is a phenomics-driven drug discovery company using machine learning to translate disease biology. Partnerships with healthcare and life science leaders enhance research. Their patent-pending Contingent-AI addresses bias detection, improving analysis. Combining in silico and in vivo work accelerates precise drug discovery. BioSymetrics, a remote-first company with clusters in Toronto and Boston.
BioSymetrics pioneers AI-driven target discovery and precision medicine. By bridging human and model system data, utilizing machine learning, and validating new targets in vivo, they accelerate drug …
Posted Artificial Intelligence Drug Discovery Precision Medicine
Last Updated
BioSymetrics’ Elion Machine Learning & Experimental Validation platform integrates machine learning and experimental validation for phenomics-driven drug discovery. Their patented Contingent …
Posted AI & Machine Learning Drug Discovery
Last Updated
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm